The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysisCOVID-19 치료제의 치료 효과 및 안전성: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-04-232022-09-11 Journal: Medicine [Category] SARS, 치료제, [키워드] 95% CI ACEi ACEi/ARB addition antiviral medicine caused Chloroquine chloroquine/hydroxychloroquine Clinical improvement Clinical symptoms clinical trial Cochrane Library conducted control group coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients COVID-19 treatment discharge rate drug effective drug effective drugs Efficiency eligible end point evaluate had no Hydroxychloroquine indicated involved measure medication Meta-analysis Mortality no significant effect Patient reduce mortality Region Serious Adverse Event Serious Adverse Events significant effect Spread systematic review therapeutic effect Treatment Trial whole body [DOI] 10.1097/MD.0000000000025532 PMC 바로가기 [Article Type] Meta-Analysis
Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in ChinaResearch Article Published on 2021-03-032022-10-28 Journal: Open Medicine [Category] COVID-19, [키워드] ACEi/ARB age analyzed Angiotensin-converting enzyme Antibiotic therapy antihypertensive drugs antiviral therapy blocker C-reactive protein China clinical Clinical features Clinical outcome collected Combination common Community Computed tomography conducted Corticosteroid cough COVID-19 COVID-19 patient COVID-19 patients CRP D-dimer demonstrated effective enrolled Epidemiology fatigue feature Fever Gender general treatment greater Ground glass opacity groups Health hospital hypertension hypertensive hypertensive patient IL-6 increased risk Inflammatory response initial International laboratory data lung median age Mild mild case morbidity and mortality no significant difference normotensive patchy Patient patients plasma receptor reported Result Safe SARS-CoV-2 severe cases severe COVID-19 severe group severe viral pneumonia significantly Spread statistically significant Symptom the median therapy treated Treatment Viral pneumonia was used with COVID-19 Wuhan [DOI] 10.1515/med-2021-0225 PMC 바로가기 [Article Type] Research Article
To Curb the Progression of Fatal COVID-19 Course—Dream or RealityArticle Published on 2021-02-272023-06-18 Journal: Current hypertension reports [Category] MERS, [키워드] ACEi/ARB COVID-19 glycocalyx heparin spironolactone [DOI] 10.1007/s11906-021-01130-z PMC 바로가기
Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of HypertensionCOVID-19 환자를 대상으로 한 레닌-안지오텐신계 억제제의 무작위 시험에 대한 전향적 메타분석 프로토콜: 국제고혈압 학회(International Society of Hypertension)의 주도Article Published on 2021-02-162022-08-31 Journal: BMJ Open [Category] meta-analysis, 임상, [키워드] ACE inhibitor ACE inhibitors ACEi ACEi/ARB Admission all-cause mortality Analysis Angiotensin II approval ARB ARBs Cardiology cardiovascular event Cardiovascular events clinical decision Comorbidities contribute Controlled controlled trials country COVID-19 Decision making drug Efficacy eligible Ethics Ethnicity Follow-up followed by Formal Guidance Health policy hypertension identify include inclusion criteria infected with SARS-CoV-2 Informed consent inhibitor initiated intensive care mechanical ventilation Meta-analysis occur outcome Patient patients with COVID-19 peer-reviewed performed Primary outcome Prospective protocol public health randomised randomised controlled trial Randomised controlled trials Randomised trial RCT RCTs receptor receptor blocker recruitment renin-angiotensin system responsibility secondary Secondary outcomes smoking smoking status Society study duration therapy Trial widespread [DOI] 10.1136/bmjopen-2020-043625 PMC 바로가기 [Article Type] Article
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19: A Meta-Analysis and Systematic ReviewCardiology Published on 2021-02-042022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 95% CI ACEi/ARB age AHA angiotensin-converting enzyme inhibitor ARB average benefit C-reactive protein (CRP Cardiology cardiovascular diseases cardiovascular prevention Cochrane Library college control group control groups coronavirus disease COVID 19 COVID-19 COVID-19 severity CRP D-dimer decrease disease severity female group heart hypertension in the global context Increased increased mortality Infection Inflammation Inflammatory marker microcirculation and inflammation Mortality no significant difference Odds ratio outcome patients patients with COVID-19 Protective protective effect RAS receptor reported Result review Sample size searched severity severity of COVID-19 signaling pathway statistically significant statistically significant difference study population Support System virulence were assessed with COVID-19 worsened [DOI] 10.7759/cureus.13124 PMC 바로가기 [Article Type] Cardiology
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19Research Paper Published on 2020-12-152022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, SARS, [키워드] ACEi/ARB Acute cardiac injury addition age Angiotensin-converting enzyme blocker cardiac injury cardiac troponin Characteristics clinical Clinical characteristics Comorbidities confounders correlation COVID-19 creatinine had more high risk hypertension in-hospital mortality independent Inflammatory response lower risk Mortality Older outcome Patient patients with COVID-19 PROTECT receiving receptor risk severe coronavirus disease severe COVID-19 significantly higher therapy [DOI] 10.18632/aging.104019 PMC 바로가기 [Article Type] Research Paper
Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use and COVID-19: Time to Change Practice or Keep Gathering Data?Editorial Published on 2020-12-032023-07-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, [키워드] ACEi/ARB COVID-19 hypertension Kidney injury Respiratory failure [DOI] 10.1093/cid/ciaa819 PMC 바로가기 [Article Type] Editorial
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France장기간 ACE 억제제/ARB 사용은 중증 COVID-19 환자의 중증 신장 기능 장애 및 급성 신장 손상과 관련이 있습니다: 프랑스 북동부의 추천 센터 코호트 결과Article Published on 2020-12-032022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 바이오마커, [키워드] 95% CI 95% confidence interval ACE ACEi ACEi/ARB acute kidney Acute kidney injury Acute respiratory failure Analysis angiotensin angiotensin receptor blocker Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor ARB association biochemical Biomarker center characteristic consecutive patient consecutive patients converting enzyme inhibitor coronavirus disease Coronavirus disease 2019 COVID-19 creatinine daily dose diagnosed disease Enzyme inhibitor evaluated France heart increase in increased risk independent predictors inflammatory reaction influence kidney Lisinopril liver dysfunction liver dysfunctions Logistic regression analysis longitudinal cohort study lung marker multivariable nitrogen Occurrence Odds ratio outcomes Patient patients performed phosphorus predict predictor receiver operating characteristic receptor receptor blocker Referral repeated measures Respiratory failure Result retrospective risk SARS-CoV-2 severe coronavirus disease severe COVID-19 severity treated urea urea nitrogen were assessed [DOI] 10.1093/cid/ciaa677 PMC 바로가기 [Article Type] Article
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular diseaseObservational Study Published on 2020-12-012022-10-05 Journal: European journal of heart failure [Category] SARS, 임상, [키워드] ACE ACE inhibitor ACE2 ACE2 expression ACE2 mRNA ACEi/ARB Analysis angiotensin-converting enzyme 2 angiotensin-converting enzyme inhibitor ARB assist association biopsy blocker cardiovascular disease cardiovascular diseases cell entry Comorbidities Coronary artery disease Coronavirus disease 2019 correlated COVID-19 COVID-19 pandemic Deleterious demonstrated enzyme expression Factor grafting heart heart failure increase in independent left Left ventricular assist device morbidity and mortality mRNA expression Myocardial pandemic Patient patients treated patients with COVID-19 polymerase chain Protective Quantitative receptor reduced Regulation SARS-CoV-2 significantly significantly increased therapy treated Treatment Trial ventricular White blood cell widespread [DOI] 10.1002/ejhf.2020 PMC 바로가기 [Article Type] Observational Study
The characteristics and outcomes of 681 severe cases with COVID-19 in China중국 코로나19 중증환자 681명의 특징과 결과Article Published on 2020-12-012022-09-11 Journal: Journal of critical care [Category] 바이오마커, [키워드] ACEi ACEi/ARB Admission Arbidol AUC blockers C-reactive protein cardiovascular cardiovascular disease CD3 Characteristics China clinical Clinical characteristics collected Combination confirmed case confirmed cases COVID-19 COVID-19 patient COVID-19 patients CRP death died effective enrolled epidemiological feature Laboratory Lactate lactate dehydrogenase LDH lymphocyte male median age Mortality myocardial injury neutrophil Neutrophil-to-lymphocyte ratio NLR on admission outcome Patient predicted Predictive Protective Ratio ribavirin SARS-CoV-2 Severe case severe COVID-19 severe COVID-19 patient severe COVID-19 patients study participant Study participants survival T cell T cells therapeutic Treatment treatments with COVID-19 β-blocker β-blockers [DOI] 10.1016/j.jcrc.2020.07.003 PMC 바로가기 [Article Type] Article